Kazibwe Joseph, Tran Phuong Bich, Annerstedt Kristi Sidney
Department of Global Public Health, Karolinska Institutet, Solna, Sweden.
The Health and Social Protection Action Research and Knowledge Sharing Network (SPARKS), Solna, Sweden.
Health Res Policy Syst. 2021 Jun 21;19(1):96. doi: 10.1186/s12961-021-00732-y.
The chronic nature of noncommunicable diseases (NCD) and costs associated with long-term care can result in catastrophic health expenditure for the patient and their household pushing them deeper into poverty and entrenching inequality in society. As the full financial burden of NCDs is not known, the objective of this study was to explore existing evidence on the financial burden of NCDs in low- and middle-income countries (LMICs), specifically estimating the cost incurred by patients with NCDs and their households to inform the development of strategies to protect such households from catastrophic expenditure.
This systematic review followed the PRISMA guidelines, PROSPERO: CRD42019141088. Eligible studies published between 1st January 2000 to 7th May 2020 were systematically searched for in three databases: Medline, Embase and Web of Science. A two-step process, comprising of qualitative synthesis proceeded by quantitative (cost) synthesis, was followed. The mean costs are presented in 2018 USD.
51 articles were included, out of which 41 were selected for the quantitative cost synthesis. Most of the studies were cross-sectional cost-of-illness studies, of which almost half focused on diabetes and/or conducted in South-East Asia. The average total costs per year to a patient/household in LMICs of COPD, CVD, cancers and diabetes were $7386.71, $6055.99, $3303.81, $1017.05, respectively.
This review highlighted major data and methodological gaps when collecting data on costs of NCDs to households along the cascade of care in LMICs. More empirical data on cost of specific NCDs are needed to identify the diseases and contexts where social protection interventions are needed most. More rigorous and standardised methods of data collection and costing for NCDs should be developed to enable comprehensive and comparable evidence of the economic and financial burden of NCDs to patients and households in LMICs. The available evidence on costs reveals a large financial burden imposed on patients and households in seeking and receiving NCD care and emphasizes the need for adequate and reliable social protection interventions to be implemented alongside Universal Health Coverage.
非传染性疾病(NCD)的慢性性质以及与长期护理相关的费用,可能导致患者及其家庭出现灾难性医疗支出,使他们陷入更深的贫困,并加剧社会不平等。由于非传染性疾病的全部经济负担尚不清楚,本研究的目的是探索低收入和中等收入国家(LMICs)非传染性疾病经济负担的现有证据,具体估算非传染性疾病患者及其家庭所产生的费用,以为制定保护此类家庭免受灾难性支出影响的策略提供依据。
本系统评价遵循PRISMA指南,国际前瞻性系统评价注册平台(PROSPERO)注册号:CRD42019141088。在三个数据库(Medline、Embase和Web of Science)中系统检索2000年1月1日至2020年5月7日发表的符合条件的研究。采用两步法,先进行定性综合,再进行定量(成本)综合。平均成本以2018年美元表示。
纳入51篇文章,其中41篇被选用于定量成本综合分析。大多数研究为横断面疾病成本研究,其中近一半聚焦于糖尿病和/或在东南亚开展。在低收入和中等收入国家,慢性阻塞性肺疾病(COPD)、心血管疾病(CVD)、癌症和糖尿病患者/家庭每年的平均总成本分别为7386.71美元、6055.99美元、3303.81美元、1017.05美元。
本综述强调了在低收入和中等收入国家收集非传染性疾病家庭护理成本数据时存在的主要数据和方法学差距。需要更多关于特定非传染性疾病成本的实证数据,以确定最需要社会保护干预措施的疾病和背景。应开发更严格和标准化的非传染性疾病数据收集和成本核算方法,以便全面、可比地了解低收入和中等收入国家非传染性疾病给患者和家庭带来的经济和财务负担。现有的成本证据显示,患者和家庭在寻求和接受非传染性疾病护理方面承受着巨大的经济负担,并强调需要在全民健康覆盖的同时实施充分且可靠的社会保护干预措施。